Clinical use of electronic portal imaging to analyse tumor motion variation during a 3D-conformal prostate cancer radiotherapy using online target verification and implanted markers
Purpose: To evaluate the daily treatment setup variation and the interfraction and intrafraction prostate motion with portal imaging and implanted fiducial markers during irradiation with a 3D conformal radiotherapy for localized prostate cancer patients.
Methods: By remote verification, shifts from isocenteric positioning and inter/intra-fraction prostate motion were investigated for 34 patients treated supine with escalated dose conformal radiotherapy. To limit the effect of inter-fraction prostate motion, patients were planned and treated with an empty rectum and a comfortably full bladder. Daily pre-therapy and treatment electronic portal images were obtained for anterior and lateral treatment fields according to an on-line target localization protocol using three gold markers. From these images, random and systematic set-up errors were measured by matching corresponding patients’ gold markers on reference digitally reconstructed radiographs (DRR). Superior-inferior, anterior-posterior and lateral motions were measured from the displacement of the gold markers implanted into the prostate before planning. A planning target volume (PTV) was derived to account for the measured prostate motion and field placement deviations.
Results: Analysis of 1,278 portal images to determine changes in the radiation field during the course of treatment. From the data, random isocenter positioning deviations were 2.66 mm, 2.78 mm and 2.59 mm for vertical, lateral and longitudinal movements respectively. The systematic deviations were 3.15 mm, 3.09 mm and 2.52 mm for vertical, lateral and longitudinal movements respectively. From the verification process, it was realized that 44.7%, 42.8% and 31.4% of the vertical, lateral and longitudinal prostate migrations respectively needed correction/shift.
Conclusion: Random set-up errors were small using real-time isocenter placement corrections. Inter-fraction prostate motion remained the largest source of treatment error, and observed motion was greatest at the laterals. In the absence of real-time pre-treatment imaging of the prostate position, using sequential portal films of implanted gold markers, portions of the PTV is missed and surrounding tissues not spared. This research improves quality assurance by confirming the prostate position within the treatment field over the course of therapy.
Cite this article as: Acquah GF, Gustavsson M, Doudoo CO, Agbeve RK, Schiestl B. Clinical use of electronic portal imaging to analyze tumor motion variation during a 3D-conformal prostate cancer radiotherapy using online target verification and implanted markers. Int J Cancer Ther Oncol 2014; 2(4):02044. DOI: 10.14319/ijcto.0204.4
Hanks GE, Hanlon AL, Schultheiss TE, et al. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 1998; 41:501-10.
Pollack A, Zagars GK. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys 1997; 39:1011-8.
Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys1998; 41:491-500.
Zelefsky MJ, Wallner KE, Ling CC, et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 1999; 17:517-22.
Herman MG, Balter JM, Jaffray DA, et al. Clinical use of electronic portal imaging: report of AAPM Radiation Therapy Committee Task Group 58. Med Phys 2001; 28:712-37.
McKenzie AL, van Herk M, Mijnheer B. The width of margins in radiotherapy treatment plans. Phys Med Biol 2000; 45:3331-42.
Hanley J, Lumley MA, Mageras GS, et al. Measurement of patient positioning errors in three-dimensional conformal radiotherapy of the prostate. Int J Radiat Oncol Biol Phys 1997; 37:435-44.
Mageras GS. Introduction: management of target localization uncertainties in external-beam therapy. Semin Radiat Oncol 2005; 15:133-5.
International Commission on Radiation Units and Measurements (ICRU). Prescribing, Recording and reporting photon beam therapy, ICRU report 50. Bethesda, Maryland: ICRU Publications; 1993:1-71.
International Commission on Radiation Units and Measurements (ICRU). Prescribing, Recording and reporting photon beam therapy (supplement to ICRU report 50), ICRU Report 62. Bethesda, Maryland: ICRU Publications; 1999: 1-52.
Murphy MJ, Balter J, Balter S, et al. The management of imaging dose during image-guided radiotherapy: report of the AAPM Task Group 75. Med Phys 2007; 34:4041-63.
Balter JM, Sandler HM, Lam K, et al. Measurement of prostate movement over the course of routine radiotherapy using implanted markers. Int J Radiat Oncol Biol Phys 1995; 31:113-8.
Acquah GF. The use of gold markers and electronic portal imaging for radiotherapy verification in prostate cancer patients: Sweden Ghana Medical Centre experience. Int J Cancer Ther Oncol 2014; 2:020112.
Bel A, Vos PH, Rodrigus PT, et al. High-precision prostate cancer irradiation by clinical application of an offline patient setup verification procedure, using portal imaging. Int J Radiat Oncol Biol Phys 1996; 35:321-32.
Dawson LA, Sharpe MB. Image-guided radiotherapy: rationale, benefits, and limitations. Lancet Oncol 2006; 7:848-58.
Dawson LA, Mah K, Franssen E, Morton G. Target position variability throughout prostate radiotherapy. Int J Radiat Oncol Biol Phys 1998; 42:1155-61.
van Lin EN, Nijenhuis E, Huizenga H, et al. Effectiveness of couch height-based patient set-up and an off-line correction protocol in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2001; 50:569-77.
Vigneault E, Pouliot J, Laverdière J, Roy J, Dorion M. Electronic portal imaging device detection of radio opaque markers for the evaluation of prostate position during megavoltage irradiation: a clinical study. Int J Radiat Oncol Biol Phys 1997; 37:205-12.
Nederveen AJ, van der Heide UA, Dehnad H, et al. Measurements and clinical consequences of prostate motion during a radiotherapy fraction. Int J Radiat Oncol Biol Phys 2002; 53:206-14.
Poggi MM, Gant DA, Sewchand W, Warlick WB. Marker seed migration in prostate localization. Int J Radiat OncolBiol Phys 2003; 56:1248-51.
Hurkmans CW, Remeijer P, Lebesque JV, Mijnheer BJ. Set-up verification using portal imaging; review of current clinical practice. Radiother Oncol 2001; 58:105-20.
Schallenkamp JM, Herman MG, Kruse JJ, Pisansky TM. Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging. Int J Radiat Oncol Biol Phys 2005; 63:800-11.
Lattanzi J, McNeeley S, Donnelly S, et al. Ultrasound-based stereotactic guidance in prostate cancer--quantification of organ motion and set-up errors in external beam radiation therapy. Comput Aided Surg 2000; 5:289-95.
Jassal K, Munshi A, Sarkar B, et al. Validation of an integrated patient positioning system: Exactrac and iViewGT on Synergy Platform. Int J Cancer Ther Oncol 2014; 2:020212.
This work is licensed under a Creative Commons Attribution 3.0 License.
International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)
© International Journal of Cancer Therapy and Oncology (IJCTO)
To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.